$YCBDSep 2, 2026, 11:36 AMAI processed8-K
cbdMD agrees to acquire Twinlab brands (Twinlab, Reserveage, Metabolife) via ABC proceeding
AI Summary
YCBD filed SEC Form 8-K. CbdMD entered a definitive asset purchase agreement to acquire operating assets and brands of Twinlab (including Twinlab, Reserveage, Metabolife and Alvita Tea) through an assignment for the benefit of creditors (ABC), subject to court approval and customary closing conditions. Based on unaudited trailing twelve months revenue through June 2026, the combined business would total approximately $30 million (about a 40% increase vs. cbdMD standalone TTM), and cbdMD expects the incremental revenue to generate positive contribution after transaction and integration costs.
Positives
- Acquisition adds recognized legacy brands (Twinlab, Reserveage, Metabolife, Alvita Tea) to cbdMD’s portfolio
- Company reports combined unaudited TTM revenue of ~ $30M, ~40% increase over cbdMD standalone TTM
- Acquired brands claim broad retail distribution (stated ~50,000 retail outlets) and strong Amazon presence
Negatives
- Transaction is being done via an ABC and requires court approval, so closing is not guaranteed
- Revenue and financial figures for the acquired brands are unaudited and presented for illustrative purposes only
- Risks flagged in the filing include integration, retention of customers/retail relationships, regulatory compliance, and potential inability to realize synergies